BPC-157 + TB-500 (20 mg Blend) Dosage Protocol
This blend combines BPC-157 (Body Protection Compound-157), a 15-amino-acid peptide derived from human gastric juice, with TB-500 (Thymosin Beta-4), a 43-amino-acid peptide involved in cell migration, angiogenesis, and wound healing. The combination provides complementary mechanisms for tissue-repair research.
âš¡ Quickstart Highlights
Dosing & Reconstitution Guide
Standard / Gradual Approach (3 mL = ~6.67 mg/mL total)
Route: Subcutaneous injection | Frequency: Once daily
| Week | Daily Dose (Total Blend) | Per-Peptide Dose | U-100 Units | Volume (mL) |
|---|---|---|---|---|
| Weeks 1–2 | 500 mcg (0.5 mg) | ~250 mcg each | 7.5 units | 0.075 mL |
| Weeks 3–4 | 666 mcg (0.67 mg) | ~333 mcg each | 10 units | 0.10 mL |
| Weeks 5–8 | 1,000 mcg (1.0 mg) | ~500 mcg each | 15 units | 0.15 mL |
Advanced / Loading Phase (Optional)
Some protocols use a higher loading dose during Weeks 1–4 based on clinical monograph recommendations for TB-500 loading dosing.
| Phase | Daily Dose (Total Blend) | Per-Peptide Dose | U-100 Units | Volume (mL) |
|---|---|---|---|---|
| Loading (Weeks 1–4) | 1,500 mcg (1.5 mg) | ~750 mcg each | 22.5 units | 0.225 mL |
| Maintenance (Weeks 5–8) | 1,000 mcg (1.0 mg) | ~500 mcg each | 15 units | 0.15 mL |
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water into a sterile insulin syringe.
- Inject slowly down the inside glass wall of the blend vial — do not direct the stream onto the powder or cause foaming.
- Gently swirl or roll until fully dissolved. Do not shake.
- Label with the reconstitution date. Refrigerate at 2–8°C (35.6–46.4°F), protected from light.
- Use within 14 days of reconstitution.
Supplies Planning
| Item | 4 Weeks | 6 Weeks | 8 Weeks |
|---|---|---|---|
| BPC-157 + TB-500 blend vials (20 mg each) | 2 vials | 3 vials | 3–4 vials |
| Insulin syringes (U-100) | 28 | 42 | 56 |
| Bacteriostatic water (10 mL) | 1 × 10 mL | 1 × 10 mL | 2 × 10 mL |
| Alcohol swabs | 1 × 100-pack | 1 × 100-pack | 2 × 100-pack |
How the Blend Works
BPC-157 Mechanism
BPC-157 is a synthetic pentadecapeptide originally isolated from human gastric juice. Preclinical research indicates it exerts cytoprotective effects across multiple organ systems, promotes angiogenesis, modulates nitric oxide pathways, and interacts with growth-factor systems involved in tissue repair. Animal models demonstrate accelerated healing of gut epithelium, tendons, ligaments, and skeletal muscle.
TB-500 (Thymosin Beta-4) Mechanism
TB-500 is a synthetic analog of Thymosin Beta-4, a naturally occurring 43-amino acid peptide found in virtually all human and animal cells. It regulates actin polymerization (key to cell motility), promotes cell migration, reduces local and systemic inflammation, and supports wound healing and tissue regeneration. TB-500 is believed to work in part by upregulating actin and the cell-surface receptor for integrin.
Complementary Action
The combination is hypothesized to provide synergistic mechanisms: BPC-157 acting primarily through NO-system and growth-factor pathways, while TB-500 works through actin regulation and direct cell migration. Together they may address tissue repair from multiple mechanistic angles simultaneously.
Research Findings & Side Effect Profile
- Tissue Repair: Both peptides demonstrate wound-healing, tendon-repair, and anti-inflammatory properties in rodent animal models.
- Gastrointestinal Support: BPC-157 shows gastroprotective and ulcer-healing effects in preclinical studies.
- Safety Profile: Preclinical data indicate a wide safety margin for BPC-157 (no lethal dose established up to ~20 mg/kg). TB-500 human tolerability studies report mild adverse events at doses up to 1,260 mg in clinical evaluation.
- WADA Status: Both BPC-157 and TB-500 are prohibited in competitive sports by WADA. Researchers in athletic contexts should be aware of this status.
- Possible Side Effects: Occasional mild injection-site reactions (redness, itching); rare reports of transient dizziness or nausea; long-term human safety data remain limited.
Storage Instructions
| State | Temperature | Duration | Notes |
|---|---|---|---|
| Lyophilized (dry blend) | −20°C (−4°F) | Up to 24 months | Dry, dark, minimize moisture |
| Reconstituted | 2–8°C (35–46°F) | Up to 14 days | Avoid freeze-thaw; light-protected |
Injection Technique
- Clean vial stopper and injection site with alcohol; allow both to dry completely.
- Pinch a skin fold. Insert 23–25 gauge needle at 45–90° into subcutaneous tissue.
- Aspiration not necessary for subcutaneous; inject slowly and steadily.
- Rotate sites: abdomen, lateral thigh, upper arm, buttocks.
- For localized injuries, inject subcutaneously near (not into) the affected area when anatomically appropriate.